Home > Boards > US OTC > Biotechs > Hepion Pharmaceuticals, Inc (HEPA)

More dilution up for vote

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
bigmike41 Member Profile
 
Followed By 2
Posts 125
Boards Moderated 0
Alias Born 11/29/10
160x600 placeholder
Hepion's rencofilstat combo reduces tumor growth in nonclinical liver cancer study Seeking Alpha - 1/26/2022 9:34:05 AM
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study GlobeNewswire Inc. - 1/26/2022 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/19/2022 10:49:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2022 10:09:33 AM
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams GlobeNewswire Inc. - 1/12/2022 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2022 6:05:16 AM
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431 GlobeNewswire Inc. - 1/6/2022 4:15:00 PM
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference GlobeNewswire Inc. - 1/5/2022 4:30:00 PM
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference GlobeNewswire Inc. - 1/5/2022 8:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2022 6:01:22 AM
FDA clears Hepion Pharma's CRV431 application for liver cancer Seeking Alpha - 12/21/2021 8:51:55 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 8:25:53 AM
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer GlobeNewswire Inc. - 12/21/2021 8:00:00 AM
Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease Seeking Alpha - 11/30/2021 8:56:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/30/2021 8:10:45 AM
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH GlobeNewswire Inc. - 11/30/2021 8:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/26/2021 6:09:13 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 11/19/2021 5:01:33 PM
Hepion Pharma reports anti-cancer activity of CRV431 in a liver cancer study in mice Seeking Alpha - 11/16/2021 9:11:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/16/2021 8:54:15 AM
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study GlobeNewswire Inc. - 11/16/2021 8:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:50:28 PM
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 8:00:00 AM
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 7:55:00 AM
Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum GlobeNewswire Inc. - 11/4/2021 8:00:00 AM
bigmike41   Thursday, 04/29/21 08:41:38 AM
Re: adtime post# 1298
Post # of 1924 
More dilution up for vote

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences